Michael Barbella, Managing Editor06.05.23
Acuitive Technologies has welcomed Vince Forlenza and Gary Fischetti to its Board of Directors as independent members. Both bring decades of medical technology experience and long track records of success.
“We are honored these successful corporate leaders share our vision and enthusiasm and are willing to provide their guidance to help us deliver a truly market disruptive bio-regenerative platform for the benefit of patients,” Acuitive Technologies Board Chairman Alex Khowaylo said. “We will benefit immediately from their insight and leadership as we move into our growth stage.”
Acuitive’s platform technology Citregen is the only synthetic, metabolically active resorbable biomaterial that stimulates the natural host tissue healing process and eliminates the inflammatory response seen with many current biodegradable materials, according to the company.
Forlenza is the former CEO and executive board chairman of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, N.J. During his nearly 40-year career with BD, Forlenza held several global executive leadership positions in the United States and Europe. He retired as CEO in January 2020 and stepped down as chairman in January 2022.
Forlenza also served as chairman of the Advanced Medical Technology Association (AdvaMed) Board of Directors from 2015 to 2017. Additionally, Forlenza serves as lead director of Moody’s Corporation, and is currently the chairman of Lehigh University's Board of Trustees. He also serves on the board of MNHI, a startup company developing obstetric devices to aid in childbirth, and MarBio, which is developing an autism screening test. Forlenza earned a bachelor of science degree in chemical engineering from Lehigh University and an MBA from Wharton Graduate School at the University of Pennsylvania.
Fischetti is the former company Group Chairman for J&J’s (Johnson & Johnson) 12 medical device businesses. During his nearly 35-year career with J&J, Fischetti held several executive leadership positions with increasing worldwide responsibility. In addition to his final role as company Group Chairman, he also served as the worldwide company Group Chairman for the family of DePuy Synthes Orthopedic companies, which included the Joint Reconstruction, Spine, Trauma, Sports Medicine, C.M.F., and Power Tools businesses. Before that, he served as the company Group Chairman for all the DePuy Orthopaedic businesses, the Codman Neuro franchise, and was the worldwide president of DePuy Spine.
Fischetti currently serves as the board chairman for Orchid Orthopedic Solutions and is a member of the boards at Extremity Medical and Conformis Corporations. Fischetti earned a bachelor of science in business administration degree in finance from Villanova University and an MBA from Rutgers University.
Founded in 2014 by four partners with decades of orthopedic experience, Acuitive Technologies is devoted to improving medical device performance and patient outcomes. Using transformative Citregen biomaterials, Acuitive offers patients cost-effective, tissue-regenerative products for musculoskeletal injury and disease.
“We are honored these successful corporate leaders share our vision and enthusiasm and are willing to provide their guidance to help us deliver a truly market disruptive bio-regenerative platform for the benefit of patients,” Acuitive Technologies Board Chairman Alex Khowaylo said. “We will benefit immediately from their insight and leadership as we move into our growth stage.”
Acuitive’s platform technology Citregen is the only synthetic, metabolically active resorbable biomaterial that stimulates the natural host tissue healing process and eliminates the inflammatory response seen with many current biodegradable materials, according to the company.
Forlenza is the former CEO and executive board chairman of BD (Becton, Dickinson and Company), a global medical technology company headquartered in Franklin Lakes, N.J. During his nearly 40-year career with BD, Forlenza held several global executive leadership positions in the United States and Europe. He retired as CEO in January 2020 and stepped down as chairman in January 2022.
Forlenza also served as chairman of the Advanced Medical Technology Association (AdvaMed) Board of Directors from 2015 to 2017. Additionally, Forlenza serves as lead director of Moody’s Corporation, and is currently the chairman of Lehigh University's Board of Trustees. He also serves on the board of MNHI, a startup company developing obstetric devices to aid in childbirth, and MarBio, which is developing an autism screening test. Forlenza earned a bachelor of science degree in chemical engineering from Lehigh University and an MBA from Wharton Graduate School at the University of Pennsylvania.
Fischetti is the former company Group Chairman for J&J’s (Johnson & Johnson) 12 medical device businesses. During his nearly 35-year career with J&J, Fischetti held several executive leadership positions with increasing worldwide responsibility. In addition to his final role as company Group Chairman, he also served as the worldwide company Group Chairman for the family of DePuy Synthes Orthopedic companies, which included the Joint Reconstruction, Spine, Trauma, Sports Medicine, C.M.F., and Power Tools businesses. Before that, he served as the company Group Chairman for all the DePuy Orthopaedic businesses, the Codman Neuro franchise, and was the worldwide president of DePuy Spine.
Fischetti currently serves as the board chairman for Orchid Orthopedic Solutions and is a member of the boards at Extremity Medical and Conformis Corporations. Fischetti earned a bachelor of science in business administration degree in finance from Villanova University and an MBA from Rutgers University.
Founded in 2014 by four partners with decades of orthopedic experience, Acuitive Technologies is devoted to improving medical device performance and patient outcomes. Using transformative Citregen biomaterials, Acuitive offers patients cost-effective, tissue-regenerative products for musculoskeletal injury and disease.
